Neurotensin: An endogenous psychostimulant? Commentary

Current Opinion in Pharmacology

Volumn 2, Issue 1, 2002, Pages 93-98

  Bérod, Anne ^a   Rostène, William ^b  

^a UNIVERSITÉ LYON 1   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; 2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; CENTRAL STIMULANT AGENT; COCAINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; G PROTEIN COUPLED RECEPTOR; METHAMPHETAMINE; NEUROLEPTIC AGENT; NEUROPEPTIDE; NEUROTENSIN; NEUROTENSIN RECEPTOR ANTAGONIST; PSYCHOSTIMULANT AGENT;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; DATA ANALYSIS; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; HUMAN; MOUSE; NEUROTRANSMISSION; NONHUMAN; PHYSIOLOGY; RAT; REGULATORY MECHANISM; REVIEW;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; NEUROTENSIN;

EID: 0036467509     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00127-8     Document Type: Note

References (57)

1. Neurotensin and neuroendocrine regulation
2. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice
3. Neurotensin: Peptide for the next millennium
4. Does neurotensin mediate the effects of antipsychotic drugs?
5. Neurotensin perchance an endogenous neuroleptic?
6. Dopamine-cell depolarisation block as a model for the therapeutic actions of antipsychotic drugs
7. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants
8. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioural sensitization: A critical review of preclinical studies
9. Pharmacology and behavioural pharmacology of the mesocortical dopamine system
10. Distinct and interactive effects of d-amphetamine and haloperidol on levels of neurotensin and its mRNA in subterritories in the dorsal and ventral striatum of the rat
11. Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique region of the striatum
12. 3 receptor deficient mice
13. Neurotensin and neurotensin receptors
14. Pharmacological, molecular and functional characterization of glial neurotensin receptors
15. Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: Evidence for the involvement of multiple receptors
16. High-affinity neurotensin receptors in the rat nucleus accumbens: Subcellular targeting and relation to endogenous ligand
17. Neurons of origin of the neurotensinergic plexus enmeshing the ventral tegmental area in rat: Retrograde labelling and in situ hybridisation combined
18. Neurotensin neurons in the ventral tegmental area project to the medial nucleus accumbens
19. Tyrosine hydroxylase-, Neurotensin, -or cholecystokinin-containing neurons in the nucleus tractus solitarii send projection fibers to the nucleus accumbens in the rat
20. Differential effect of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions
21. Morphologically distinct subpopulations of neurotensin-immunoreactive striatal neurons observed in rat following dopamine depletions and D2 receptor blockade project to the globus pallidus
22. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalmic GABA transmission: A dual-probe microdialysis study in intact conscious rat brain
23. Chronic cocaine increases neurotensin gene expression in the shell of the nucleus accumbens and in discrete regions of the striatum
24. 3 receptors on neurotensin mRNA expression in muscle accumbens
25. Effects of CNS stimulants on the vivo release of the colocalized transmitters, dopamine and neurotensin from prefrontal cortex
26. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat
27. Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens
28. Effects of prefrontal cortex microinjection of neurotensin-(8-13) on midbrain dopamine and non-dopamine cell firing
29. Neurochemical sensitization in the pathology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity
30. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies
31. Incentive-sensitization and addiction
32. Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat
33. Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens
34. 11] neurotensin applied into the ventral tegmental area on extracellular dopamine in the rat prefrontal cortex and nucleus accumbens
35. Repeated neurotensin administration in the ventral tegmental area: Effects on baseline and d-amphetamine-induced locomotor activity
36. Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens
37. Repeated activation of neurotensin receptors sensitizes to the stimulant effect of amphetamine
38. 11]neurotensin after repeated injections of the dopamine uptake inhibitor GBR 12783 in rats
39. Neurotensin: A new "reward peptide"
40. Neurotensin self-injection in the ventral tegmental area
41. Facilitation of brain stimulation reward by mesencephalic injections of neurotensin-(1-13)
42. Mesencephalic microinjections of neurotensin-(1-13) and its C-terminal fragment, neurotensin-(8-13), potentiate brain stimulation reward
43. Neurotensin blocks certain amphetamine-induced behaviors
44. Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-stimulation in the rat
45. SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin- induced behaviour and changes in dopaminergic transmission
46. Neuroanatomical site specific modulation of spontaneous motor activity by neurotensin
47. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor
48. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist
49. Role of endogeneous neurotensin in the behavioral and neuroendocrine effects of cocaine
50. Preexposure to, but not cotreatment with, the neurotensin antagonist SR48692 delays the development of cocaine sensitization
51. Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization
52. Chronic blockade of neurotensin receptors strongly reduces sensitized, but not acute, behavioural response to D-amphetamine
53. Involvement of cortical neurotensin in the regulation of rat mesocorticol-limbic dopamine neuronsL evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blackade
54. Effects of neurotensin receptor antagonist on the firing of rat ventral pallidum neurons
55. Repeated administration of the neurotensin receptor antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems
56. Neuropeptides - An overview
57. Nonpeptide antagonists of neuropeptide receptors: Tools for research and therapy